Scaling up antiretroviral therapy in South Africa: the impact of speed on survival.

@article{Walensky2008ScalingUA,
  title={Scaling up antiretroviral therapy in South Africa: the impact of speed on survival.},
  author={Rochelle P. Walensky and Robin Wood and Milton C. Weinstein and Neil Alexander Martinson and Elena Losina and Mariam O Fofana and Sue J. Goldie and Nomita Divi and Yazdan Yazdanpanah and Bingxia Wang and A. David Paltiel and Kenneth A. Freedberg},
  journal={The Journal of infectious diseases},
  year={2008},
  volume={197 9},
  pages={1324-32}
}
BACKGROUND Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012. METHODS Using a simulation model of HIV infection with South African data, we projected HIV-associated mortality with and without effective ART for an adult cohort in need of therapy (2007) and for adults who became eligible for treatment (2008-2012… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Rethinking HIV exceptionalism: the ethics of opt-out HIV testing in sub-Saharan Africa.

Bulletin of the World Health Organization • 2010
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 24 references

The demographic impact of HIV/AIDS in South Africa: national and provincial indicators

RE Dorrington, L Johnson, D Bradshaw, D.T.-J
Available at: http://www.actuarialsociety.co.za/applications/cms/ documents/file_build.asp?id 100000148. Accessed • 2006
View 10 Excerpts
Highly Influenced

New Congress can save lives, or money

D. Tutu
Available at: http://www.washingtonpost.com/wp-dyn/ content/article/2007/01/13/AR2007011300496.html. Accessed • 2007
View 1 Excerpt

Clinical benefits and costeffectiveness of antiretroviral therapy for human immunodeficiency virus-infected patients in resource-poor settings: the case of Côte d’Ivoire

S Goldie, Y Yazdanpanah, E Losina
N Engl J Med • 2006
View 2 Excerpts

MONARK trial (monotherapy Antiretroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r zidovudine/Lamivudine (AZT/3TC) in antiretroviral-naive patients

J-F Delfraissy, P Flandre, C Delaugerre
[abstract ThLB0202]. In: Program and abstracts of the XVI International AIDS Conference. Toronto, Canada, • 2006
View 2 Excerpts

South Africa's "rollout" of highly active antiretroviral therapy: a critical assessment.

Journal of acquired immune deficiency syndromes • 2006
View 2 Excerpts

Similar Papers

Loading similar papers…